Compumedics Limited · ASX:CMP

Compumedics — Shareholder Meeting (September 2014)

30 slides from Compumedics's shareholder meeting presentation, September 2014

  1. Slide 1: Compumedics Limited Corporate Presentation – September 2014

    For personal use only Compumedics Limited Corporate Presenta2on – September 2014

  2. Slide 2: Agenda

    Agenda For personal use only • Mee2ng opens • Chairman’s address • Ordinary business • Mee2ng closes

  3. Slide 3: Who is Compumedics?

    Who is Compumedics? For personal use only • Compumedics is a leading global, innovative developer and manufacturer of medical devices for: – Diagnosing sleep disorders – Monitoring neurological disorders including long-term epilepsy monitoring (LTEM) – Highly sophisticated brain research – Ultrasoni

  4. Slide 4: Directors and Executive Team Key Management

    Directors and Executive Team Key Management For personal use only David Burton, Ph.D. Execu5ve Chairman, CEO Founder, Tenure 26yrs NED Mr. David Lawson Mr. Alan Anderson Chief Financial Officer & Leading USA AKorney Company Secretary CMP Tenure : 11 yrs CMP Tenure 13 yrs Mr. Warwick Freeman Kerry Hubi

  5. Slide 5: A Tradition of Innovation

    A Tradi3on of Innova3on For personal use only Comperio DQ Summit IP SynAmps2 2004 2005 Somté 2003 2001 Siesta 802 Siesta 2000 2005 P Series 1994 S Series 1987 Somté PSG 2006 Neuvo LTM SynAmpsRT 2007 2008 CURRY6 2009 Somnilink SPAP Grael HD 2010 2010 Somté PSG 2.0 2011

  6. Slide 6: Established Client Profile

    Established Client Profile For personal use only

  7. Slide 7: Strategic Value Roadmap – Market Opportunities

    Strategic Value Roadmap – Market Opportuni3es For personal use only Core Diagnos5c Business 15 Medical Innova5ons Global Global Markets -­‐ $m 25 150 Markets -­‐ $m 450 10,000 8,000 Sleep Diagnos2cs Neurological Monitoring Brain Research 15,000 TCD Sleep Treatment Driver Vigilance eHealth

  8. Slide 8: What was achieved in the twelve months to June 2014?

    What was achieved in the twelve months to 30 June 2014? For personal use only ! NPAT of $0.9 million compared to loss of $(1.4) million for the PCP. EBITDA was a $3.0 million profit compared to $0.3 million in the PCP, as a result of ongoing efficiency gains in manufacturing, and the favourable impact

  9. Slide 9: What was achieved in the twelve months to June 2014?

    What was achieved in the twelve months to 30 June 2014? For personal use only ! The Company had sales orders of $6.0 million on-­‐hand at 30 June 2014, which it expects to con2nue to reduce during the first half of FY2015. ! The Company has substan2vely completed reloca2ng some produc2on and purchasi

  10. Slide 10: Revenue Composition at ≈$30.8m

    Revenue Composi3on at ≈$30.8m For personal use only By geographic region By product/market Tech. Europe, Supply Service, 18% USA, Items, 9% Sleep, 32% 10% 30% Asia, Brain Neuro, 32% Aust, Blood 12% Flow, Brain 18% 21% Res, 18% Compumedics sells directly to end-­‐user customers in Australia, USA and

  11. Slide 11: Historical Full Year Revenues

    Historical Full Year Revenues For personal use only Shipped and invoiced 40.0 35.0 30.0 25.0 20.0 15.0 10.0 5.0 0.0 2012 2013 2014 FY2015 Full Yr F'Cast Rev

  12. Slide 12: Historical Full Year Earnings

    Historical Full Year Earnings For personal use only NPAT EBITDA 3 5 2 4 1 3 0 2012 2013 2014 FY2015 2 -­‐1 1 -­‐2 -­‐3 0 2012 2013 2014 FC2015 -­‐4 -­‐1 NPAT F'Cast NPAT EBITDA F'Cast EBITDA

  13. Slide 13: Cash, debt & operating cash

    Cash, debt & opera3ng cash For personal use only 2.5 2 1.5 1 0.5 0 2012 2013 2014 Opera2ng cash Cash Debt

  14. Slide 14: Employee Composition at ≈130 staff

    Employee Composi3on at ≈130 staff For personal use only By geographic region By func5on Mid Quality, Asia, East, Admin 2% Sales & 2% 1% & Fin, Mark, Europe, USA, 24% 32% 12% 24% Manuf, Service, Aust, R&D, 28% 12% 41% 22% Compumedics has its Head Office in Melbourne, Australia with addi2onal offices in Ch

  15. Slide 15: Strategic Value Roadmap – Core Diagnostic Business Opportunities

    Strategic Value Roadmap – Core Diagnos3c Business Opportuni3es For personal use only Core Diagnos5c Business Global Markets -­‐ $m 25 15 150 450 Medical Innova5ons Global Markets -­‐ $m 10,000 8,000 Sleep Diagnos2cs Neurological Monitoring Brain Research TCD 15,000 Sleep Treatment Driver Vigilance e

  16. Slide 16: Growth strategies – Core business

    Growth strategies – Core business For personal use only • Building growth momentum in key global neurological monitoring markets with emphasis on LTEM through the Company’s innova2ve product plamorm and growing brand recogni2on in these new markets for the Company. • Expansion across all product lin

  17. Slide 17: Growth Strategies - Execution so far

    Growth Strategies -­‐ Execu3on so far Compumedics Clients in China For personal use only

  18. Slide 18: Earnings improvement activities

    Earnings improvement ac3vi3es For personal use only • Reloca2on of selected manufacturing ac2vi2es to lower cost regions in China and Taiwan. • Con2nue to drive component purchasing to lower cost regions in China and Taiwan. • Streamlining of logis2cs (final product assembly, tes2ng and shipment) as

  19. Slide 19: Strategic Value Roadmap – Medical Innovations Commercial Opportunities

    Strategic Value Roadmap – Medical Innova3ons Commercial Opportuni3es For personal use only 15 Core Diagnos5c Business 25 Global Markets -­‐ $m Medical Innova5ons Global 150 Markets -­‐ $m 450 10,000 8,000 Sleep Diagnos2cs Neurological Monitoring Brain Research 15,000 TCD Sleep Treatment Driver Vigil

  20. Slide 20: Medical Innovations – Sleep Treatment

    Medical Innova3ons – Sleep Treatment For personal use only • The sleep treatment technology is the most advanced of these Medical Innova2on technologies. • The SomniLink® SPAP® device has been developed in collabora2on with Medigas Italia S.r.l., Compumedics Italian distributor and also a significant

  21. Slide 21: Medical Innovations – Sleep Treatment

    Medical Innova3ons – Sleep Treatment For personal use only • About 20% of the adult popula2on globally suffer from some sleep disorder. • The global Apnoea devices market is es2mated at about USD8bn with expecta2ons it could reach close to $20bn by 2017. • Up to 100m people globally suffer from Sleep

  22. Slide 22: Medical Innovations – Driver Vigilance Assist

    Medical Innova3ons – Driver Vigilance Assist For personal use only • Compumedics has unique sleep monitoring technology which has been used to research and develop proto-­‐type systems for monitoring driver drowsiness • Fa2gue is one of the top three reasons for all road fatali2es • Car manufacturer

  23. Slide 23: Medical Innovations – Driver Vigilance Assist

    Medical Innova3ons – Driver Vigilance Assist For personal use only • Market for this technology is very large – conserva2vely es2mated at $30m for the Australian market and up to USD15bn for the global market, based on annual vehicle produc2on of some 60m vehicles a year. • Compumedics owns patents

  24. Slide 24: Medical Innovations – eHealth

    Medical Innova3ons – eHealth For personal use only • eHealth home and hospital applica5ons for exis5ng Compumedics technologies – driven by government and insurers needs to reduce the delivery costs of health services to ageing popula2ons. • Large markets – US market for exis2ng eHealth applica2ons

  25. Slide 25: Strategic Growth Execution Capitalization Pathways

    Strategic Growth Execu3on Capitaliza)on Pathways For personal use only The three principal paths available to Compumedics in order to implement the strategic growth drivers are: ! “Do it ourselves” – recapitalize the group and implement the action plans for the strategic growth drivers ourselves (we

  26. Slide 26: Comparative valuations

    Compara5ve valua5ons For personal use only Annualised Revenes and Market Cap rela5ve to Annualised Revenues 35.0 20.00 18.00 30.0 16.00 25.0 Market Cap to Revenues 14.00 Revenues -­‐ $m 12.00 20.0 10.00 15.0 8.00 10.0 6.00 4.00 5.0 2.00 -­‐ 0.00 CMP MVP UCM IPD UBI GLH MBE Revenues 29.0 9.0 0.8 3.2

  27. Slide 27: In conclusion

    In conclusion For personal use only • Core business – refocus on sales and profit growth as Asia manufacturing cost reduc2ons and clearing the sales order back-­‐log restore profitability to the Group. Consider ra2onaliza2on of the Group and demerger op2ons to provide clearer focus • Medical Innova5on

  28. Slide 28: Ordinary Business

    Ordinary Business For personal use only ! Item 1 Financial Statements and Reports ! Item 2 Re-election of Director – Mr. A Anderson ! Item 3 Adoption of Remuneration Report (non- binding resolution) ! ! Item 4 Adoption of the Medical Innovation Long- Term Performance Plan and the issuing of shares u

  29. Slide 29: Meeting closes

    Meeting closes For personal use only Refreshments and additional questions and discussion to continue in the main reception area for those interested.

  30. Slide 30: OneMedForum 2011 - San Francisco

    For personal use only OneMedForum 2011 - San Francisco Wednesday 12 January 2011

Compumedics — Shareholder Meeting (September 2014) on 6ix